Durvalumab for cancer after stopping immune therapy due to side effects
Treatments studied
Part of Cancer clinical trials.
This Phase 2 trial tests whether durvalumab (an immunotherapy) can still help treat advanced cancer after you had to stop an earlier immune checkpoint medicine because of immune-related side effects. If you’re already on a durvalumab-based study, Substudy B also looks at continuing durvalumab (with or without tremelimumab) when it’s safe for you.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced or metastatic/recurrent solid cancer that cannot be cured with standard treatment.
- You live in Canada and can travel to a participating study center for treatment and follow-up (about 1.5 hours driving distance is mentioned).
- You previously stopped an immune checkpoint medicine because of an immune-related side effect (irAE), and it has improved to grade 1 or back to your baseline.
- You finished steroid treatment for the irAE at least 28 days before starting this study, and your immune side effects are under control.
- Your cancer previously responded or stayed controlled for a meaningful time on the first immune treatment (complete response, partial response, or stable disease for at least 8 weeks).
- You meet blood and organ safety limits (for example: enough white blood cells, platelets, hemoglobin; and acceptable liver/kidney tests).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study lets people who already finished (or can no longer continue) an earlier AstraZeneca cancer treatment study keep receiving durvalumab. It tests whether continuing the same kind of treatment on a regular schedule can help keep your cancer under control.
This Phase 2 study tests whether adding propranolol to durvalumab and tremelimumab along with chemotherapy can help control advanced pancreatic cancer, liver cancer, or bile duct cancer. It aims to shrink tumors and help people live longer or feel better when the cancer can’t be cured with surgery or local treatment.
This trial studies durvalumab (an immune therapy) combined with chemotherapy to treat advanced solid tumors that have grown despite prior standard treatment or have no proven standard option. It aims to improve control of the cancer and help people live longer.
This study tests whether the immunotherapy drugs durvalumab (with or without tremelimumab) can help control hepatocellular carcinoma (liver cancer) after you receive palliative, targeted radiation. It especially focuses on people whose cancer continued to grow after, or without, certain prior immune therapies.
This trial tests adding durvalumab (an immunotherapy) after chemotherapy, surgery, and more durvalumab for people with early-stage, operable non-small cell lung cancer. It aims to see if this extra treatment helps prevent the cancer from coming back.
This trial tests whether the immunotherapy drug durvalumab can help keep limited-stage small cell lung cancer from coming back after standard treatment. You would receive durvalumab as a 'consolidation' (maintenance) therapy.
Hear when a new Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.